Dr. Martin on the Safety Profile of Bispecific T-Cell Engagers in Multiple Myeloma

Video

In Partnership With:

Thomas G. Martin, MD, discusses the safety profile of bispecific T-cell engagers in multiple myeloma.

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the safety profile of bispecific T-cell engagers (BiTEs) in multiple myeloma.

BiTEs are generally very well tolerated by patients with multiple myeloma, says Martin. In the frontline setting, agents that are associated with significant toxicities, such as neuropathy, cardiac toxicities, or renal toxicities, may not be optimal because patients with multiple myeloma often have good prognoses, Martin explains.

As such, BiTEs could be good additions to the frontline armamentarium because they could limit toxicity for patients, Martin says. Although the agents confer mild cytokine release syndrome and neurologic toxicity, few treatment-related deaths have been reported in the clinical trials evaluating these agents, concludes Martin.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD